量化投资凭借理性、科学、情绪稳定的特质，近年来受到越来越多投资者的欢迎。作为国内成立最早的一批量化私募，九坤投资在十数年的量化长跑中， 荣获逾150项各类行业奖项，涵盖"金牛奖"、"英华奖"、"金阳光奖"、"金长江奖"等，持续保持领先规模和业绩竞争力。 私募排排网数据显示，截至8月底，九坤投资旗下有业绩显示的13只产品今年来收益均值为***%，成立以来业绩同样表现亮眼。其中"九坤日享中证1000 指数增强1号"今年来收益位居第1，该产品近五年超额收益高达***%，运作以来累计收益高达***%，体现了九坤投资在指增赛道上优秀的长期投资能 力。 | 排名 | 产品简称 | 公司简称 | 三级策略 | 基金经理 | 产品规模 近5年收益 (万元) | 近5年超额 | | --- | --- | --- | --- | --- | --- | --- | | | 九坤日享中证1000指数增 强1号 | | 九坤投资 中证1000指增 | 姚齐聪 | | | | | 明沈量化中小盘增强1号B | | 明泫投资 中证1000指增 | 聚煮明,解 | | | | | 英份额 | | | 环宇 | | | | m | 天演奏 ...

Core Insights - The average return of private equity fund managers in the past year reached 21.84%, significantly outperforming the market [2] - Stock fund managers showed the highest average return of 25.52%, benefiting from the recovery of the A-share market since "924" [2][4] - Fund managers with assets under management between 0-5 billion yuan had the best performance, with average returns of 23.38% [2][4] By Strategy - Stock Strategy: 1471 managers, 2853 products, total AUM of 2330.34 billion yuan, average return of 25.52% [4] - Futures and Derivatives: 393 managers, 652 products, total AUM of 393.50 billion yuan, average return of 17.27% [4] - Multi-Asset: 297 managers, 531 products, total AUM of 476.29 billion yuan, average return of 19.32% [4] - Bond: 179 managers, 409 products, total AUM of 445.17 billion yuan, average return of 9.70% [4] - Combination Funds: 63 managers, 94 products, total AUM of 42.59 billion yuan, average return of 24.17% [4] By Company Size - Managers with over 10 billion yuan AUM: 114 managers, 586 products, total AUM of 998.51 billion yuan, average return of 20.66% [4] - Managers with 5-10 billion yuan AUM: 400 managers, 707 products, total AUM of 468.51 billion yuan, average return of 23.38% [4] - Managers with 0-5 billion yuan AUM: 1442 managers, 2104 products, total AUM of 750.51 billion yuan, average return of 22.52% [4] Top Performers - Wang Chen from Jiukun Investment topped the list among managers with over 10 billion yuan AUM [5][9] - Wu Xing from Shenzhen Kaifeng Investment led the 50-100 billion yuan category [10][11] - Chen Yu from Shennong Investment ranked first among 20-50 billion yuan managers, focusing on innovative drugs [15][19] - Sun Jie from Nengjing Investment led the 10-20 billion yuan category [22][23] - Hu Shiyuan from Wantao Private Equity topped the 5-10 billion yuan category [29][30] - Tan Guanhua from Hainan Xiangyuan Private Equity led the 0-5 billion yuan category [30][32]